Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B.
Acquired hemophilia
Diagnosis and therapy algoritm
ICU management
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
24
09
2021
revised:
29
10
2021
accepted:
01
11
2021
pubmed:
16
11
2021
medline:
20
4
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
There is a dire need to develop an algorithm to improve the recognition of acquired hemophilia A and B (AHA and AHB) in clinical practice. Initial and intensive care unit (ICU) management of the disorder is particular and represents a challenge for the internist/hematologist and the ICU physician. A delay in the proper treatment of bleeding episodes can lead to a life-threatening event. Expert advice should be sought as soon as possible. Succesful resolution involves accurate diagnosis, bleeding control with hemostatic and immunotherapy, and eradication of the autoantibodies to improve overall survival. Current treatment guidelines are based on the literature in the form of cases and observational studies due to a lack of randomized controlled trials. AH can be triggered by many pathologies, presenting as a paraneoplastic syndrome in case of malignancies or as surgical associated acquired hemophilia (SAHA). We have reviewed the literature from 2015 to 2021 regarding the new case reports to further assess if there is an improvement in the clinical approach.
Identifiants
pubmed: 34776294
pii: S0268-960X(21)00113-2
doi: 10.1016/j.blre.2021.100907
pii:
doi:
Substances chimiques
Autoantibodies
0
Hemostatics
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100907Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.